IO Biotech, Inc.

NASDAQ:IOBT

1.19 (USD) • At close September 19, 2024
Bedrijfsnaam IO Biotech, Inc.
Symbool IOBT
Munteenheid USD
Prijs 1.19
Beurswaarde 78,398,283
Dividendpercentage 0%
52-weken bereik 0.733 - 2.098
Industrie Biotechnology
Sector Healthcare
CEO Dr. Mai-Britt Zocca Ph.D.
Website https://www.iobiotech.com

An error occurred while fetching data.

Over IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as

Vergelijkbare Aandelen

Assertio Holdings, Inc. logo

Assertio Holdings, Inc.

ASRT

1.35 USD

Ikena Oncology, Inc. logo

Ikena Oncology, Inc.

IKNA

1.71 USD

DarioHealth Corp. logo

DarioHealth Corp.

DRIO

1 USD

AVITA Medical, Inc. logo

AVITA Medical, Inc.

RCEL

9.96 USD

Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Ltd.

SLGL

0.702 USD

Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc.

CTXR

0.548 USD

Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc.

OVID

1.17 USD

ProPhase Labs, Inc. logo

ProPhase Labs, Inc.

PRPH

2.51 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)